Larry W. Moreland

54.8k total citations · 7 hit papers
291 papers, 18.9k citations indexed

About

Larry W. Moreland is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Larry W. Moreland has authored 291 papers receiving a total of 18.9k indexed citations (citations by other indexed papers that have themselves been cited), including 210 papers in Rheumatology, 65 papers in Immunology and 63 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Larry W. Moreland's work include Rheumatoid Arthritis Research and Therapies (168 papers), Systemic Lupus Erythematosus Research (80 papers) and Monoclonal and Polyclonal Antibodies Research (60 papers). Larry W. Moreland is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (168 papers), Systemic Lupus Erythematosus Research (80 papers) and Monoclonal and Polyclonal Antibodies Research (60 papers). Larry W. Moreland collaborates with scholars based in United States, Canada and United Kingdom. Larry W. Moreland's co-authors include Michael Schiff, Edward Keystone, Roy Fleischmann, Mark C. Genovese, Arthur L. Weaver, Michael E. Weinblatt, Stanley Cohen, Joan M. Bathon, Joel M. Kremer and Richard W. Martin and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Genetics.

In The Last Decade

Larry W. Moreland

279 papers receiving 18.0k citations

Hit Papers

Adalimumab, a fully human... 1997 2026 2006 2016 2003 2000 1997 1999 2003 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    2003 1.4k citations Larry W. Moreland, Michael H. Weisman et al. profile →
  2. A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
    2000 1.4k citations Larry W. Moreland et al. New England Journal of Medicine profile →
  3. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein
    1997 1.3k citations Larry W. Moreland et al. New England Journal of Medicine profile →
  4. Etanercept Therapy in Rheumatoid Arthritis
    1999 1.1k citations Larry W. Moreland et al. Annals of Internal Medicine profile →
  5. Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
    2003 807 citations Joel M. Kremer, René Westhovens et al. New England Journal of Medicine profile →
  6. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
    2002 573 citations Larry W. Moreland et al. profile →
  7. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
    2006 558 citations Joel M. Kremer, Larry W. Moreland et al. Annals of Internal Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larry W. Moreland United States 59 12.2k 5.0k 4.7k 2.4k 2.3k 291 18.9k
Michael H. Weisman United States 67 14.9k 1.2× 5.0k 1.0× 6.2k 1.3× 1.9k 0.8× 2.4k 1.0× 340 22.2k
Vibeke Strand United States 73 15.4k 1.3× 5.6k 1.1× 6.3k 1.3× 2.0k 0.9× 2.6k 1.1× 522 22.9k
Ben A. C. Dijkmans Netherlands 83 18.3k 1.5× 6.1k 1.2× 6.3k 1.3× 2.1k 0.9× 2.3k 1.0× 332 25.0k
Ferdinand C. Breedveld Netherlands 67 15.2k 1.2× 5.4k 1.1× 5.4k 1.1× 2.6k 1.1× 2.0k 0.9× 182 21.9k
Daniel Aletaha Austria 64 15.0k 1.2× 5.4k 1.1× 4.7k 1.0× 2.4k 1.0× 2.4k 1.0× 327 21.2k
Harvinder S. Luthra United States 34 13.7k 1.1× 3.6k 0.7× 4.8k 1.0× 1.7k 0.7× 2.3k 1.0× 96 20.4k
Edward Keystone Canada 69 17.0k 1.4× 7.8k 1.6× 6.8k 1.4× 4.2k 1.8× 3.1k 1.4× 404 24.5k
E. William St. Clair United States 55 9.1k 0.7× 3.2k 0.6× 5.3k 1.1× 2.3k 1.0× 1.7k 0.7× 170 16.5k
Juan J. Gómez‐Reino Spain 72 10.7k 0.9× 3.8k 0.8× 5.3k 1.1× 1.7k 0.7× 1.4k 0.6× 364 19.8k
Donald M. Mitchell United States 15 14.1k 1.2× 3.9k 0.8× 3.7k 0.8× 1.5k 0.6× 2.3k 1.0× 22 19.3k

Countries citing papers authored by Larry W. Moreland

Since Specialization
Citations

This map shows the geographic impact of Larry W. Moreland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry W. Moreland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry W. Moreland more than expected).

Fields of papers citing papers by Larry W. Moreland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry W. Moreland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry W. Moreland. The network helps show where Larry W. Moreland may publish in the future.

Co-authorship network of co-authors of Larry W. Moreland

This figure shows the co-authorship network connecting the top 25 collaborators of Larry W. Moreland. A scholar is included among the top collaborators of Larry W. Moreland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry W. Moreland. Larry W. Moreland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhu, Lei, Larry W. Moreland, & Dana P. Ascherman. (2024). Cross-sectional association between social and demographic factors and disease activity in rheumatoid arthritis. BMC Rheumatology. 8(1). 2–2. 1 indexed citations
3.
Robinson, William H., David Fiorentino, Leland W.K. Chung, et al.. (2024). Cutting-edge approaches to B-cell depletion in autoimmune diseases. Frontiers in Immunology. 15. 1454747–1454747. 13 indexed citations
4.
Holers, V. Michael, Rachel M. Frank, Michael J. Zuscik, et al.. (2024). Decay-Accelerating Factor Differentially Associates With Complement-Mediated Damage in Synovium After Meniscus Tear as Compared to Anterior Cruciate Ligament Injury. Immune Network. 24(2). e17–e17. 2 indexed citations
5.
Cuthbertson, David, Simon Carette, Nader Khalidi, et al.. (2022). Vitamin D status in ANCA-associated vasculitis. Rheumatology Advances in Practice. 7(1). rkad021–rkad021. 2 indexed citations
6.
Rodríguez-Pla, Alicia, Roscoe L. Warner, David Cuthbertson, et al.. (2019). Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. The Journal of Rheumatology. 47(7). 1001–1010. 21 indexed citations
7.
Boers, Maarten, Jasvinder A. Singh, Stacey S. Cofield, et al.. (2018). A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials. Arthritis Care & Research. 71(2). 319–322. 3 indexed citations
8.
Krischer, Jeffrey P., Peter F. Cronholm, Cristina Burroughs, et al.. (2017). Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. Journal of Medical Internet Research. 19(2). e50–e50. 22 indexed citations
9.
Tamhane, Ashutosh, David T. Redden, Gerald McGwin, et al.. (2013). Comparison of the Disease Activity Score Using Erythrocyte Sedimentation Rate and C-reactive Protein in African Americans with Rheumatoid Arthritis. The Journal of Rheumatology. 40(11). 1812–1822. 26 indexed citations
10.
Morgan, Sarah, et al.. (2009). The Safety of Flavocoxid, a Medical Food, in the Dietary Management of Knee Osteoarthritis. Journal of Medicinal Food. 12(5). 1143–1148. 32 indexed citations
11.
Yu, Fang, Jeffrey R. Curtis, Graciela S. Alarcón, et al.. (2009). Vitamin D Status and Its Associations with Disease Activity and Severity in African Americans with Recent-onset Rheumatoid Arthritis. The Journal of Rheumatology. 37(2). 275–281. 95 indexed citations
12.
Moreland, Larry W.. (2004). Rheumatology and immunology therapy : A to Z essentials. Springer eBooks. 2 indexed citations
13.
Kremer, Joel M., René Westhovens, Marc Léon, et al.. (2003). Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig. New England Journal of Medicine. 349(20). 1907–1915. 807 indexed citations breakdown →
14.
Vignon, Éric & Larry W. Moreland. (2003). How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?. Osteoarthritis and Cartilage. 12. 61–62. 3 indexed citations
15.
Moreland, Larry W. & Paul Emery. (2003). TNF[alpha]-inhibition in the treatment of rheumatoid arthritis. 2 indexed citations
16.
Moreland, Larry W.. (2001). Rheumatoid arthritis : epidemiology, pathogenesis and treatment. 3 indexed citations
17.
Ruderman, Eric, et al.. (2000). A PHASE III TRIAL OF ETANERCEPT vs METHOTREXATE (MTX) IN EARLY RHEUMATOID ARTHRITIS (ENBREL ERA TRIAL). 40(2). 229. 32 indexed citations
18.
Seibold, James R., Joseph H. Korn, Robert W. Simms, et al.. (2000). Recombinant Human Relaxin in the Treatment of Scleroderma. Annals of Internal Medicine. 44 indexed citations
19.
Clegg, Daniel O., James C. Reading, Maureen D. Mayes, et al.. (1994). Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma.. PubMed. 21(1). 105–10. 13 indexed citations
20.
Moreland, Larry W., Anthony G. DiBartolomeo, & James E. Brick. (1988). Rheumatoid vasculitis with intrarenal aneurysm formation.. PubMed. 15(5). 845–9. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael H. Weisman Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Ferdinand C. Breedveld Breakdown of academic impact, for papers by Daniel Aletaha Breakdown of academic impact, for papers by Harvinder S. Luthra Breakdown of academic impact, for papers by Edward Keystone Breakdown of academic impact, for papers by E. William St. Clair Breakdown of academic impact, for papers by Juan J. Gómez‐Reino Breakdown of academic impact, for papers by Donald M. Mitchell
Rankless by CCL
2026